论文部分内容阅读
为了探讨降纤酶治疗急性脑梗死的疗效及与治疗时间窗的关系 ,以及该药对患者血液中的血小板聚集功能和纤维蛋白原的影响。将经确诊的急性脑梗死患者 72例分为降纤酶组和丹参组两组。降纤酶组 38例 ,使用降纤酶治疗 ,10单位加入生理盐水 2 5 0mL中静脉滴注 ,每曰 1次 ,连用 3天 ;丹参组 34例 ,使用丹参粉剂治疗 ,0 .4g加入 5 %葡萄糖液 5 0 0mL中静脉滴注 ,每曰 1次 ,连用 14天。两组病例均于用药前后分别测定患者血液中的血小板聚集功能和纤维蛋白原 ,于治疗后 1周末和 4周末评定疗效 ,此时把两组病例根据起病后至用药时间分为 2 4h内和 2 4～ 72h两部分观察其疗效的变化。结果发现 ,降纤酶组用药前血小板聚集率为 6 5 .6 %± 5 .3% ,纤维蛋白原为 4.78± 0 .42g/L ;用药后血小板聚集率为 45 .8%± 4.9% ,纤维蛋白原为 3.16± 0 .35g/L ,用药前后差异极为显著(P <0 .0 0 1)。丹参组用药前血小板聚集率为 6 0 .4%± 1.9% ,用药后为 49.0 %± 10 .3% ,亦有差异 (P <0 .0 1) ;但降纤酶组用药前后的差异明显高于丹参组 (P <0 .0 5 ,P <0 .0 1)。临床疗效观察发现 ,神经功能改善方面 ,在用药 1周末最明显 ,4周末两组比较无显著差异。但在发病 2 4h内用药者 ,4周末降纤酶组的神经功能改善仍优于丹参组。此结果
To investigate the efficacy of defibrase in the treatment of acute cerebral infarction and its relationship to the time window of treatment and the effect of this drug on platelet aggregation and fibrinogen in the blood of patients. Will be diagnosed 72 cases of acute cerebral infarction patients were divided into defibrase group and Salvia group two groups. Defibrase group 38 cases, the use of defibrase treatment, 10 units by adding normal saline 250mL intravenous infusion, once each for 3 days; Salvia group 34 cases, the use of Salvia powder treatment, 0.4g added 5 % Glucose solution 500mL intravenous infusion, each said 1, once every 14 days. Two groups of patients were measured before and after treatment in patients with blood platelet aggregation and fibrinogen in the treatment of 1 weekend and 4 weeks to assess the efficacy of the two groups of patients according to the time from onset to treatment within 24 hours And 2 4 ~ 72h two parts observed changes in its efficacy. The results showed that the platelet aggregation rate of defibrase group was 65.6% ± 5.3% and that of fibrinogen was 4.78 ± 0.42g / L before treatment; the platelet aggregation rate was 45.8% ± 4.9% Fibrinogen was 3.16 ± 0.35g / L, the difference was significant before and after treatment (P <0.001). Salvia miltiorrhiza group before administration of platelet aggregation rate of 60.4% ± 1.9%, after treatment was 49.0% ± 10.3%, there are differences (P <0.01); but defibrase group before and after treatment were significantly different Higher than Salvia group (P <0.05, P <0.01). Clinical observation found that neurological improvement, the most obvious at 1 week after treatment, no significant difference between the two groups at 4 weeks. However, within 24 hours after onset of medication, 4-week defibrase activity was still better than Danshen group. This result